Latest News
JANUARY 2012
Hospitalisation rates and costs associated with atherothrombotic disease in France and Germany are high, especially so for patients with PAD
A recent paper has been published explaining the economic burden of atherothrombosis in patients with multiple risk factors, including under evaluated patients with peripheral arterial disease (PAD). The findings show that the two year hospitalisation costs were highest for those with PAD.
At Dialog Devices we have created an innovative and non-invasive medical device called Padd® for rapid and simple assessment of PAD using low power near infra-red light to assess blood volume changes in the foot, before and after raising the leg. As it is so simple to use, Padd® can be used in a primary care setting making testing convenient for the patient.
For further information please visit:
DECEMBER 2011
North West England to host trials of new products to boost long-term healthcare
A team at Royal Liverpool and Broadgreen University Hospitals NHS Trust, led by consultant vascular surgeon Mr Rao Vallabhaneni, will be evaluating the Padd® device. Currently patients must be referred to hospital for diagnosis. Padd® offers a rapid and simple way to detect and monitor the condition in a doctor’s surgery or clinic.
For more information please visit:
